Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Cancer and Leukemia Group B National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00070135 |
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus and methotrexate after the transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well giving fludarabine together with busulfan followed by a donor stem cell transplant works in treating older patients with acute myeloid leukemia that is in the first complete remission.
Condition | Intervention | Phase |
---|---|---|
Leukemia |
Biological: filgrastim Biological: graft-versus-tumor induction therapy Drug: busulfan Drug: fludarabine phosphate Drug: methotrexate Drug: tacrolimus Procedure: peripheral blood stem cell transplantation |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | A Phase II Study Of Allogeneic Transplant For Older Patients With AML In First Morphologic Complete Remission Using A Non-Myeloablative Preparative Regimen |
Estimated Enrollment: | 61 |
Study Start Date: | January 2004 |
Estimated Primary Completion Date: | April 2005 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study.
Graft-versus-host disease (GVHD) prophylaxis: Patients receive oral or IV tacrolimus twice daily starting on days -2, with tapering between days 90-120, and stopping by days 150-180. Patients also receive methotrexate IV on days 1, 3, 6,and 11 and rabbit antithymocyte globulin (Thymoglobulin) IV over 4-6 hours on days -4 through
PROJECTED ACCRUAL: A total of 61 patients will be accrued for this study.
Ages Eligible for Study: | 60 Years to 74 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of acute myeloid leukemia (AML) in first morphologic complete remission
Morphologic complete remission achieved within the past 6 months and after no more than 2 courses of induction chemotherapy
Complete morphologic remission is defined by all of the following criteria:
No more than 2 courses of prior consolidation therapy
The following donors will be allowed:
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Bilirubin less than 2 mg/dL*
Renal
Cardiovascular
Pulmonary
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
United States, California | |
UCSF Helen Diller Family Comprehensive Cancer Center | |
San Francisco, California, United States, 94115 | |
United States, Delaware | |
CCOP - Christiana Care Health Services | |
Newark, Delaware, United States, 19713 | |
Tunnell Cancer Center at Beebe Medical Center | |
Lewes, Delaware, United States, 19958 | |
United States, Georgia | |
Blood and Marrow Transplant Group of Georgia | |
Atlanta, Georgia, United States, 30342 | |
United States, Maryland | |
Greenebaum Cancer Center at University of Maryland Medical Center | |
Baltimore, Maryland, United States, 21201 | |
Union Hospital Cancer Program at Union Hospital | |
Elkton MD, Maryland, United States, 21921 | |
United States, Massachusetts | |
Dana-Farber/Brigham and Women's Cancer Center | |
Boston, Massachusetts, United States, 02115 | |
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute | |
Boston, Massachusetts, United States, 02115 | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 | |
United States, Minnesota | |
Masonic Cancer Center at University of Minnesota | |
Minneapolis, Minnesota, United States, 55455 | |
United States, Missouri | |
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis | |
Saint Louis, Missouri, United States, 63110 | |
United States, New Jersey | |
Cancer Institute of New Jersey at Cooper - Voorhees | |
Voorhees, New Jersey, United States, 08043 | |
United States, New York | |
CCOP - North Shore University Hospital | |
Manhasset, New York, United States, 11030 | |
Don Monti Comprehensive Cancer Center at North Shore University Hospital | |
Manhasset, New York, United States, 11030 | |
Long Island Jewish Medical Center | |
New Hyde Park, New York, United States, 11042 | |
Monter Cancer Center of the North Shore-LIJ Health System | |
Lake Success, New York, United States, 11042 | |
Roswell Park Cancer Institute | |
Buffalo, New York, United States, 14263-0001 | |
United States, North Carolina | |
Wake Forest University Comprehensive Cancer Center | |
Winston-Salem, North Carolina, United States, 27157-1096 | |
United States, Ohio | |
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center | |
Columbus, Ohio, United States, 43210-1240 | |
United States, Pennsylvania | |
Fox Chase Cancer Center - Philadelphia | |
Philadelphia, Pennsylvania, United States, 19111-2497 | |
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital | |
Pittsburgh, Pennsylvania, United States, 15224-1791 |
Study Chair: | Steven M. Devine, MD | Arthur G. James Cancer Hospital & Richard J. Solove Research Institute |
Responsible Party: | Cancer and Leukemia Group B ( Richard L. Schilsky ) |
Study ID Numbers: | CDR0000330001, CALGB-100103 |
Study First Received: | October 3, 2003 |
Last Updated: | April 14, 2009 |
ClinicalTrials.gov Identifier: | NCT00070135 History of Changes |
Health Authority: | United States: Federal Government |
adult acute myeloid leukemia in remission secondary acute myeloid leukemia adult acute monocytic leukemia (M5b) adult acute erythroid leukemia (M6) adult acute megakaryoblastic leukemia (M7) adult acute minimally differentiated myeloid leukemia (M0) adult acute myeloblastic leukemia with maturation (M2) |
adult acute myeloblastic leukemia without maturation (M1) adult acute myelomonocytic leukemia (M4) adult acute monoblastic leukemia (M5a) adult acute myeloid leukemia with t(8;21)(q22;q22) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with 11q23 (MLL) abnormalities |
Leukemia, Monocytic, Acute Antimetabolites Immunologic Factors Acute Myelomonocytic Leukemia Folate Acute Monoblastic Leukemia Tacrolimus Leukemia, Myeloid, Acute Vitamin B9 Leukemia Acute Erythroblastic Leukemia Acute Myelocytic Leukemia Acute Myeloid Leukemia, Adult Neoplasm Metastasis Methotrexate |
Congenital Abnormalities Alkylating Agents Leukemia, Myeloid Fludarabine monophosphate Folinic Acid Folic Acid Antagonists Immunosuppressive Agents Leukemia, Myelomonocytic, Acute Folic Acid Leukemia, Erythroblastic, Acute Busulfan Fludarabine Antineoplastic Agents, Alkylating Antirheumatic Agents Di Guglielmo's Syndrome |
Antimetabolites Antimetabolites, Antineoplastic Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Tacrolimus Reproductive Control Agents Leukemia, Myeloid, Acute Leukemia Therapeutic Uses Abortifacient Agents Methotrexate Dermatologic Agents Alkylating Agents |
Nucleic Acid Synthesis Inhibitors Neoplasms by Histologic Type Enzyme Inhibitors Fludarabine monophosphate Leukemia, Myeloid Folic Acid Antagonists Abortifacient Agents, Nonsteroidal Immunosuppressive Agents Pharmacologic Actions Neoplasms Busulfan Myeloablative Agonists Fludarabine Antineoplastic Agents, Alkylating Antirheumatic Agents |